Top

Published in:

01-06-2012 | NON-THEMATIC REVIEW

Translation initiation in colorectal cancer

Authors: Armen Parsyan, Greco Hernández, Sarkis Meterissian

Published in: Cancer and Metastasis Reviews | Issue 1-2/2012

Abstract

Colorectal cancers (CRC) are one of the most common causes of morbidity and mortality in high-income countries. Targeted screening programs have resulted in early treatment and a substantial decrease in mortality. However, treatment strategies for CRC still require improvement. Understanding the etiology and pathogenesis of CRC would provide tools for improving treatment of patients with this disease. It is only recently that deregulation of the protein synthesis apparatus has begun to gain attention as a major player in cancer development and progression. Among the numerous steps of protein synthesis, deregulation of the process of translation initiation appears to play a key role in cancer growth and proliferation. This manuscript discusses a fascinating and rapidly growing field exploring translation initiation as a fundamental component in CRC development and progression and summarizing CRC treatment perspectives based on agents targeting translation initiation.

Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN. International Journal of Cancer (Journal international du cancer), 127(12), 2893–2917. doi:10.1002/ijc.25516.

Engstrom, P. F., Benson, A. B., 3rd, Chen, Y. J., Choti, M. A., Dilawari, R. A., Enke, C. A., et al. (2005). Colon cancer clinical practice guidelines in oncology. [Guideline Practice Guideline]. Journal of the National Comprehensive Cancer Network, 3(4), 468–491.PubMed

Edwards, M. S., Chadda, S. D., Zhao, Z., Barber, B. L., & Sykes, D. P. (2012). A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland, 14(2), e31–e47. doi:10.1111/j.1463-1318.2011.02765.x.CrossRef

Peeters, M., & Price, T. (2011). Biologic therapies in the metastatic colorectal cancer treatment continuum—Applying current evidence to clinical practice. Cancer Treatment Reviews. doi:10.1016/j.ctrv.2011.08.002.

Van Loon, K., & Venook, A. P. (2011). Adjuvant treatment of colon cancer: What is next? [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Current Opinion in Oncology, 23(4), 403–409. doi:10.1097/CCO.0b013e3283479c83.PubMedCrossRef

Mathews, M. B., Sonenberg, N., & Hershey, J. W. B. (2007). Translational control in biology and medicine. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.

Parsyan, A., Svitkin, Y., Shahbazian, D., Gkogkas, C., Lasko, P., Merrick, W. C., et al. (2011). mRNA helicases: The tacticians of translational control. [Research Support, Non-U.S. Gov’t Review]. Nature Reviews. Molecular Cell Biology, 12(4), 235–245. doi:10.1038/nrm3083.PubMedCrossRef

Sonenberg, N., & Hinnebusch, A. G. (2009). Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t Review]. Cell, 136(4), 731–745. doi:10.1016/j.cell.2009.01.042.PubMedCrossRef

Jackson, R. J., Hellen, C. U., & Pestova, T. V. (2010). The mechanism of eukaryotic translation initiation and principles of its regulation. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Nature Reviews. Molecular Cell Biology, 11(2), 113–127. doi:10.1038/nrm2838.PubMedCrossRef

10.

Shatkin, A. J. (1976). Capping of eucaryotic mRNAs. Cell, 9(4 PT 2), 645–653.PubMedCrossRef

11.

Silvera, D., Formenti, S. C., & Schneider, R. J. (2010). Translational control in cancer. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review]. Nature Reviews. Cancer, 10(4), 254–266. doi:10.1038/nrc2824.PubMedCrossRef

12.

De Benedetti, A., & Graff, J. R. (2004). eIF-4E expression and its role in malignancies and metastases. [Research Support, Non-U.S. Gov't Review]. Oncogene, 23(18), 3189–3199. doi:10.1038/sj.onc.1207545.PubMedCrossRef

13.

Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990). Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature, 345(6275), 544–547.PubMedCrossRef

14.

Lazaris-Karatzas, A., Smith, M. R., Frederickson, R. M., Jaramillo, M. L., Liu, Y. L., Kung, H. F., et al. (1992). Ras mediates translation initiation factor 4E-induced malignant transformation. Genes & Development, 6(9), 1631–1642.CrossRef

15.

Zimmer, S. G., DeBenedetti, A., & Graff, J. R. (2000). Translational control of malignancy: The mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. [Research Support, U.S. Gov't, P.H.S. Review]. Anticancer Research, 20(3A), 1343–1351.PubMed

16.

Joseph, P., O'Kernick, C. M., Othumpangat, S., Lei, Y. X., Yuan, B. Z., & Ong, T. M. (2004). Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Molecular Carcinogenesis, 40(3), 171–179. doi:10.1002/mc.20033.PubMedCrossRef

17.

Rosenwald, I. B., Chen, J. J., Wang, S., Savas, L., London, I. M., & Pullman, J. (1999). Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Oncogene, 18(15), 2507–2517. doi:10.1038/sj.onc.1202563.PubMedCrossRef

18.

Berkel, H. J., Turbat-Herrera, E. A., Shi, R., & de Benedetti, A. (2001). Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. [Research Support, U.S. Gov't, P.H.S.]. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 10(6), 663–666.

19.

Yang, S. X., Hewitt, S. M., Steinberg, S. M., Liewehr, D. J., & Swain, S. M. (2007). Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncology Reports, 17(2), 281–287.PubMed

20.

Xi, Y., Formentini, A., Nakajima, G., Kornmann, M., & Ju, J. (2008). Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. [Research Support, Non-U.S. Gov't Validation Studies]. Oncology Reports, 19(1), 257–262.PubMed

21.

Slattery, M. L., Lundgreen, A., Herrick, J. S., Caan, B. J., Potter, J. D., & Wolff, R. K. (2011). Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: Additional support for a TGF-beta-signaling pathway. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Carcinogenesis, 32(3), 318–326. doi:10.1093/carcin/bgq245.PubMedCrossRef

22.

Rosenwald, I. B., Wang, S., Savas, L., Woda, B., & Pullman, J. (2003). Expression of translation initiation factor eIF-2alpha is increased in benign and malignant melanocytic and colonic epithelial neoplasms. Cancer, 98(5), 1080–1088. doi:10.1002/cncr.11619.PubMedCrossRef

23.

Yoon, C. H., Lee, E. S., Lim, D. S., & Bae, Y. S. (2009). PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. [Research Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the United States of America, 106(19), 7852–7857. doi:10.1073/pnas.0812148106.PubMedCrossRef

24.

Kim, S. H., Gunnery, S., Choe, J. K., & Mathews, M. B. (2002). Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. [Research Support, U.S. Gov't, P.H.S.]. Oncogene, 21(57), 8741–8748. doi:10.1038/sj.onc.1205987.PubMedCrossRef

25.

Garcia, M. A., Carrasco, E., Aguilera, M., Alvarez, P., Rivas, C., Campos, J. M., et al. (2011). The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. [Research Support, Non-U.S. Gov't]. PloS One, 6(8), e23887. doi:10.1371/journal.pone.0023887.PubMedCrossRef

26.

Stolfi, C., Sarra, M., Caruso, R., Fantini, M. C., Fina, D., Pellegrini, R., et al. (2010). Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine. [Research Support, Non-U.S. Gov't]. Gastroenterology, 138(1), 221–230. doi:10.1053/j.gastro.2009.08.062.PubMedCrossRef

27.

Shor, B., Zhang, W. G., Toral-Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., et al. (2008). A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Research, 68(8), 2934–2943. doi:10.1158/0008-5472.CAN-07-6487.PubMedCrossRef

28.

Hinnebusch, A. G. (2006). eIF3: a versatile scaffold for translation initiation complexes. [Research Support, N.I.H., Intramural Review]. Trends in Biochemical Sciences, 31(10), 553–562. doi:10.1016/j.tibs.2006.08.005.PubMedCrossRef

29.

Liu, Z., Dong, Z., Yang, Z., Chen, Q., Pan, Y., Yang, Y., et al. (2007). Role of eIF3a (eIF3 p170) in intestinal cell differentiation and its association with early development. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Differentiation; Research in Biological Diversity, 75(7), 652–661. doi:10.1111/j.1432-0436.2007.00165.x.PubMedCrossRef

30.

Haybaeck, J., O'Connor, T., Spilka, R., Spizzo, G., Ensinger, C., Mikuz, G., et al. (2010). Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Research, 30(4), 1047–1055.PubMed

31.

Goh, S. H., Hong, S. H., Lee, B. C., Ju, M. H., Jeong, J. S., Cho, Y. R., et al. (2011). eIF3m expression influences the regulation of tumorigenesis-related genes in human colon cancer. [Research Support, N.I.H., Intramural]. Oncogene, 30(4), 398–409. doi:10.1038/onc.2010.422.PubMedCrossRef

32.

Wu, D., Matsushita, K., Matsubara, H., Nomura, F., & Tomonaga, T. (2011). An alternative splicing isoform of eukaryotic initiation factor 4H promotes tumorigenesis in vivo and is a potential therapeutic target for human cancer. [Research Support, Non-U.S. Gov't]. International Journal of Cancer. Journal International du Cancer, 128(5), 1018–1030.PubMedCrossRef

33.

Nakagawa, Y., Morikawa, H., Hirata, I., Shiozaki, M., Matsumoto, A., Maemura, K., et al. (1999). Overexpression of rck/p54, a DEAD box protein, in human colorectal tumours. [Research Support, Non-U.S. Gov't]. British Journal of Cancer, 80(5-6), 914–917. doi:10.1038/sj.bjc.6690441.PubMedCrossRef

34.

Shahbazian, D., Parsyan, A., Petroulakis, E., Hershey, J., & Sonenberg, N. (2010). eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. [Research Support, Non-U.S. Gov't]. Cell Cycle, 9(20), 4106–4109.PubMedCrossRef

35.

Caraglia, M., Park, M. H., Wolff, E. C., Marra, M., & Abbruzzese, A. (2011). eIF5A isoforms and cancer: Two brothers for two functions? Amino Acids. doi:10.1007/s00726-011-1182-x.

36.

Henderson, A., & Hershey, J. W. (2011). The role of eIF5A in protein synthesis. [Editorial]. Cell Cycle, 10(21), 3617–3618. doi:10.4161/cc.10.21.17850.PubMedCrossRef

37.

Taylor, C. A., Sun, Z., Cliche, D. O., Ming, H., Eshaque, B., Jin, S., et al. (2007). Eukaryotic translation initiation factor 5A induces apoptosis in colon cancer cells and associates with the nucleus in response to tumour necrosis factor alpha signalling. [Research Support, Non-U.S. Gov't]. Experimental Cell Research, 313(3), 437–449. doi:10.1016/j.yexcr.2006.09.030.PubMedCrossRef

38.

Park, M. H., Lee, Y. B., & Joe, Y. A. (1997). Hypusine is essential for eukaryotic cell proliferation. [Review]. Biological Signals, 6(3), 115–123.PubMedCrossRef

39.

Ignatenko, N. A., Yerushalmi, H. F., Pandey, R., Kachel, K. L., Stringer, D. E., Marton, L. J., et al. (2009). Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Cancer Genomics & Proteomics, 6(3), 161–175.

40.

Malina, A., Cencic, R., & Pelletier, J. (2011). Targeting translation dependence in cancer. [Research Support, Non-U.S. Gov't Review]. Oncotarget, 2(1-2), 76–88.PubMed

41.

Konicek, B. W., Stephens, J. R., McNulty, A. M., Robichaud, N., Peery, R. B., Dumstorf, C. A., et al. (2011). Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Research, 71(5), 1849–1857. doi:10.1158/0008-5472.CAN-10-3298.PubMedCrossRef

42.

Roulin, D., Cerantola, Y., Dormond-Meuwly, A., Demartines, N., & Dormond, O. (2010). Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. [Research Support, Non-U.S. Gov't]. Molecular Cancer, 9, 57. doi:10.1186/1476-4598-9-57.PubMedCrossRef

43.

Gulhati, P., Bowen, K. A., Liu, J., Stevens, P. D., Rychahou, P. G., Chen, M., et al. (2011). mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. [Research Support, N.I.H., Extramural]. Cancer Research, 71(9), 3246–3256. doi:10.1158/0008-5472.CAN-10-4058.PubMedCrossRef

44.

O'Reilly, T., McSheehy, P. M., Wartmann, M., Lassota, P., Brandt, R., & Lane, H. A. (2011). Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anti-Cancer Drugs, 22(1), 58–78. doi:10.1097/CAD.0b013e3283400a20.PubMedCrossRef

45.

Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., et al. (2002). 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. The Journal of Biological Chemistry, 277(16), 13907–13917. doi:10.1074/jbc.M110782200.PubMedCrossRef

46.

Fujishita, T., Aoki, K., Lane, H. A., Aoki, M., & Taketo, M. M. (2008). Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. [Research Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the United States of America, 105(36). doi:10.1073/pnas.0800041105.

47.

Johnson, S. M., Gulhati, P., Rampy, B. A., Han, Y., Rychahou, P. G., Doan, H. Q., et al. (2010). Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. Journal of the American College of Surgeons, 210(5), 767–776. doi:10.1016/j.jamcollsurg.2009.12.008.PubMedCrossRef

48.

Aljada, A., & Mousa, S. A. (2012). Metformin and neoplasia: Implications and indications. Pharmacology and Therapeutics, 133(1), 108–115. doi:10.1016/j.pharmthera.2011.09.004.PubMedCrossRef

49.

Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., et al. (2010). Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. [Research Support, Non-U.S. Gov't]. Molecular Carcinogenesis, 49(7), 662–671. doi:10.1002/mc.20637.PubMedCrossRef

50.

Zakikhani, M., Dowling, R. J., Sonenberg, N., & Pollak, M. N. (2008). The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. [Research Support, Non-U.S. Gov't]. Cancer Prevention Research, 1(5), 369–375. doi:10.1158/1940-6207.CAPR-08-0081.PubMedCrossRef

51.

Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., et al. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. [Research Support, N.I.H., Extramural]. Cancer Research, 67(14), 6745–6752. doi:10.1158/0008-5472.CAN-06-4447.PubMedCrossRef

52.

Dumstorf, C. A., Konicek, B. W., McNulty, A. M., Parsons, S. H., Furic, L., Sonenberg, N., et al. (2010). Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Molecular Cancer Therapeutics, 9(12), 3158–3163. doi:10.1158/1535-7163.MCT-10-0413.PubMedCrossRef

53.

Hu, J., Straub, J., Xiao, D., Singh, S. V., Yang, H. S., Sonenberg, N., et al. (2007). Phenethyl isothiocyanate, a cancer chemopreventive constituent of cruciferous vegetables, inhibits cap-dependent translation by regulating the level and phosphorylation of 4E-BP1. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Cancer Research, 67(8), 3569–3573. doi:10.1158/0008-5472.CAN-07-0392.PubMedCrossRef

54.

Yang, Y. J., Zhang, Y. L., Wang, J. D., Lai, Z. S., Wang, Q. Y., & Cui, H. H. (2003). [Role of eukaryotic initiation factor-4E (eIF-4E) in regulation of expression of NF-appaB and its subsequent influence on transcription and activity of heparanase in human colon adenocarcinoma cell line]. [Research Support, Non-U.S. Gov't]. Ai zheng = Aizheng = Chinese Journal of Cancer, 22(10), 1023–1029. doi:1000467X2003101023.PubMed

55.

Yang, Y. J., Zhang, Y. L., Li, X., Dan, H. L., Lai, Z. S., Wang, J. D., et al. (2003). Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line: LS-174T. [Research Support, Non-U.S. Gov't]. World Journal of Gastroenterology, 9(8), 1707–1712.PubMed

56.

Yang, Y. J., Zhang, Y. L., Lai, Z. S., Cui, H. H., Zhong, S. S., & Liu, Y. H. (2003). Effect of eIF-4E inhibition on heparanase mRNA and its expression in colon adenocarcinoma cell. [Research Support, Non-U.S. Gov't]. Di 1 jun yi da xue xue bao = Academic Journal of the First Medical College of PLA, 23(7), 655–658.PubMed

Title: Translation initiation in colorectal cancer
Authors: Armen Parsyan
Greco Hernández
Sarkis Meterissian
Publication date: 01-06-2012
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1-2/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9349-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2012

BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype

Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms

Bee venom in cancer therapy

Positive lymph nodes do not metastasize

S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence

EMT in carcinoma progression and dissemination: Facts, unanswered questions, and clinical considerations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer